Airway Management in Children Undergoing Adenotonsillectomies
NCT ID: NCT00570414
Last Updated: 2009-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
128 participants
INTERVENTIONAL
2007-03-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The laryngeal mask was introduced in 1983 as an alternative to the endotracheal tube. In 1990, the flexible, reinforced laryngeal mask airway was introduced, intended for use during surgical procedures involving the mouth and throat. The laryngeal mask airway has several potential advantages over the endotracheal tube. It is inserted blindly, without laryngoscopy. This leads to reduced oropharyngeal or laryngeal stimulation and injury, and therefore minimal activation of respiratory and circulatory reflexes. The laryngeal mask airway can be placed without the use of muscle relaxants, avoiding potential side effects such as apnea, hyperkalemia and anaphylaxis. In addition the laryngeal mask airway can remain in the throat until the patient awakes, virtually eliminating the danger of postoperative aspiration.
Several international studies have described the advantages of the laryngeal mask airway over endotracheal intubation during ear, nose and throat surgery in children. The general impression is that there is a widespread routine implementation of the laryngeal mask airway. In Norway, however, this practice has been limited. As far as we know, only Namsos Hospital uses this procedure as its first choice. At Telemark Hospital we tested the use of laryngeal mask airway on 150 patients between May and December 2006. The results so far have been promising, and we have had no serious complications.
Hypothesis:
In children undergoing adenotonsillectomies, a laryngeal mask airway provides greater patient satisfaction (judged by reduced pain, nausea and vomiting) and greater effectivity (judged by reduced time in surgery), compared with the endotracheal tube. The laryngeal mask provides as much as or greater secure airway management measured by desaturations/Sp02\<92% and/or use of suxamethonium and bronchiolytic drugs.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Propofol on Respiratory Adverse Events During Extubation in Children Undergoing Tonsil Adenoidectomy
NCT05769842
Impact of Using a Cuffed Endotracheal Tube on Limiting the Risk of Airway Fire
NCT01285804
Physical Activity Tracking in Paediatric Elective Tonsillectomy
NCT03174496
Anesthetic Gas Leakage in Children During Tonsillectomy: a Comparison of Cuffed and Uncuffed Tracheal Tubes
NCT02725164
Postoperative Sore Throat in the Pediatric Population.
NCT03389776
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Preoperative: Age, height, weight, medication, asthma/allergy, possible current respiratory infection
Peroperative: Type of procedure, tube size/laryngeal mask, type of tongue blade, highest/lowest SpO2, highest/lowest ET CO2, highest/lowest pulse, length of surgery, total operating room time, operator, medication. Reason must be given if converting from laryngeal mask to tube; lack of visibility for operator, laryngeal mask not possible to place, unacceptable leakage before placing tongue blade, occlusion after placement of tongue blade.
Postoperative: Pain judged by need for opiates (VAS, crying, agitation, tachycardia), nausea judged by gagging/vomiting, total time in recovery, rebleeding judged by reoperation.
Anesthesia:
Induction: Alfentanil 20 microg/kg body weight Propofol 3-4 mg/kg body weight Or: Sevoflurane/N2O mask induction with MAC 1-2
Maintenance: Alfentanil 5-10 microg/kg body weight every 8-10 minutes Sevoflurane/N2O equivalent to 1-1.5 MAC Acetaminophen supp 40 mg/kg body weight, max 2 g. Dexamethasone 0.15mg/kg body weight Xylocaine 1mg/kg body weight
Emergence: Morphine 100-200 mikrog/kg body weight
Postoperative: Morphine 50-100 microg/kg body weight
Post-discharge: Acetaminophen tbl 15 mg/kg body weight x 3 Or: Acetaminophen supp 20 mg/kg body weight x 3
Patient booklet:
A patient booklet will be produced for each patient. The booklet will contain only the patient's initials, age and research number. After the booklets are filled out, they will be stored in a locked facility by one of the examining physicians, and the code to the patient's name will be stored and locked separately by one of the researchers. The code will be destroyed at the end of the research study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Laryngeal mask airway (LMA)
Laryngeal mask airway
Airway management by the use of the flexible, reinforced laryngeal mask airway
2
Endotracheal tube (ETT)
Endotracheal tube
Airway management by the use of endotracheal tube
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laryngeal mask airway
Airway management by the use of the flexible, reinforced laryngeal mask airway
Endotracheal tube
Airway management by the use of endotracheal tube
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Elective adenotomy, tonsillectomy or combined adenotonsillectomy under general anesthesia.
* Written and oral informed parental consent.
Exclusion Criteria
* Weight \< 10 kg or weight \> 60 kg.
* Congenital malformations of the mouth or throat.
3 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sykehuset Telemark
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sykehuset Telemark
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Simen Doksrød, MD
Role: PRINCIPAL_INVESTIGATOR
Sykehuset Telemark
Peter Heidt, PhD
Role: STUDY_DIRECTOR
Namsos Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sykehuset Telemark, Clinic of emergency medicin
Porsgrunn, Telemark, Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
s-07031b
Identifier Type: -
Identifier Source: secondary_id
s8197.03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.